Semaglutide Complete Guide 2026: Dosing, Results & Safety

You've seen the Ozempic headlines. You've heard about the shortages. Now you're trying to cut through the noise and figure out whether semaglutide is worth it, what dosing actually looks like, and where to get it.

This guide covers all of that: how it works, what the clinical trials showed with actual numbers, the side effect reality, and how to evaluate sources. Talk to a doctor before starting anything new.

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. It triggers insulin release, slows gastric emptying, and signals your brain that you're full.

Your body's natural GLP-1 breaks down in about 2 minutes. Semaglutide mimics that hormone but stays active for roughly 7 days, which is why once-weekly injections work. The molecule is a 31-amino-acid peptide modified with a C18 fatty acid chain that lets it bind to albumin and resist breakdown.

FDA-approved brand names:

Oral semaglutide (Rybelsus) also exists for diabetes, but bioavailability is substantially lower than injectable forms. For weight loss, injectable is the standard.

The STEP trials are the benchmark. Here's what the numbers actually say.

STEP 1 (Wilding et al., NEJM 2021): 1,961 adults with obesity, no diabetes. Average weight loss of 14.9% of body weight over 68 weeks on 2.4mg weekly. That's roughly 15.3 kg (33.7 lbs) for the average participant. The placebo group lost 2.4%.

For context: the strongest lifestyle interventions achieve 5-7% weight loss. Older medications like phentermine average 3-5%. Semaglutide is a different category.

STEP 2 (Davies et al., Lancet 2021): Adults with type 2 diabetes showed 9.6% weight loss. Lower than STEP 1 because diabetes impairs the full GLP-1 response.

STEP 4 (Rubino et al., NEJM 2021): This is the one most guides skip. When participants stopped semaglutide after 20 weeks, they regained roughly two-thirds of the weight within 12 months. The data is clear: this is a long-term treatment, not a short course.

Most compounded semaglutide users follow this same protocol. Some practitioners stay 2 extra weeks at each dose level to reduce GI side effects. If you're nausea-sensitive, slower escalation is worth it.

Meaningful weight loss occurs across the 1.0-2.4mg range. Some people find their sweet spot at 1.0mg with acceptable side effects and stay there.

Injection technique: Subcutaneous (SubQ) in the abdomen, thigh, or upper arm. Rotate sites each week. Use a 29-31 gauge needle, 4-8mm length.

GI side effects are the primary complaint, most pronounced during dose escalation. From STEP 1 data (semaglutide vs placebo):

Most GI effects improve after 4-8 weeks at a stable dose. Slow escalation is the best mitigation. Smaller meals and lower-fat foods during escalation also help.

Serious but rare concerns:

Who should not use semaglutide:

When Ozempic and Wegovy hit shortage status in 2022, 503A and 503B compounding pharmacies legally filled the gap. The FDA moved to end semaglutide compounding in early 2025 as Novo Nordisk claimed supply recovery, but legal challenges from compounders and telehealth companies created delays. The situation remains unsettled as of mid-2026 and varies by state.

What matters when evaluating any compounded semaglutide source:

For verified suppliers with testing documentation, check our [semaglutide peptide page](/peptide/semaglutide) and [supplier comparison tool](/compare).

Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed 20.9% average weight loss at 15mg, meaningfully higher than semaglutide's 14.9%.

The tradeoff: tirzepatide is newer with less long-term safety data, and it's harder to find at comparable prices. Semaglutide has a longer track record. See our [semaglutide vs tirzepatide comparison](/blog/semaglutide-vs-tirzepatide) for the full breakdown.

Current semaglutide 5mg pricing across the suppliers we track:

Pinnacle costs a bit more but publishes batch COAs directly on product pages before purchase. Ascension is the best value if you're comfortable requesting COAs manually.

How long does semaglutide take to work?

Appetite reduction typically shows up in weeks 1-2. Meaningful weight loss (5%+) usually becomes apparent by weeks 8-12. The STEP 1 trial ran 68 weeks to reach maximum effect.

What happens when you stop semaglutide?

Most people regain the weight. STEP 4 showed roughly two-thirds of lost weight returned within 12 months of stopping. If you plan to stop, having a maintenance protocol matters.

Is 0.5mg enough for weight loss?

Some people see real results at 0.5-1.0mg. The STEP trials used 2.4mg for maximum effect, but meaningful weight loss occurs across the dosing range. Start low and evaluate response at each level before escalating.

Can you stack semaglutide with other peptides?

There's no formal trial data on combining semaglutide with research peptides. The most common pairing in practice is BPC-157 for GI support during escalation. The rationale is reasonable given [BPC-157's gut-healing research](/blog/bpc-157-complete-guide), but we haven't tested this combination ourselves.

Is compounded semaglutide the same molecule as Wegovy?

The active molecule is identical. The difference is in manufacturing standards, excipients, and formulation precision. Brand Wegovy goes through Novo Nordisk's full quality system. Compounders replicate the molecule independently, which is why third-party COA documentation matters.

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384(11):989-1002.

2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. NEJM. 2021;384(14):1283-1292.

3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387(3):205-216.

4. FDA Drug Approval Package: Wegovy (semaglutide) injection, 2.4mg. NDA 215256. June 2021.

5. Davies M et al. Semaglutide 2.4mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021;397(10278):971-984.

6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM. 2016;375(19):1834-1844.